<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844506</url>
  </required_header>
  <id_info>
    <org_study_id>ISA-P53-CTX</org_study_id>
    <secondary_id>EUDRACT 2007-007734-19</secondary_id>
    <secondary_id>CCMO NL21308.000.07</secondary_id>
    <nct_id>NCT00844506</nct_id>
  </id_info>
  <brief_title>p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer</brief_title>
  <acronym>ISA-P53-CTX</acronym>
  <official_title>p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ISA Pharmaceuticals B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of cyclophosphamide to the
      treatment with the p53-SLP vaccine improves clinical efficacy and immunogenicity of the
      p53-SLP vaccine in ovarian cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical responses to the p53 synthetic long peptide vaccine preceded by cyclophosphamide will be assessed by measurement of serum CA-125 levels and CT-scan.</measure>
    <time_frame>day 105 - 126 after first gift of cyclophosphamide</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity will be evaluated by assessing induction and frequency of p53-specific T cells by proliferation and IFN-γ ELISPOT.</measure>
    <time_frame>after fourth immunization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the vaccine preceded by cyclophosphamide will be assessed by monitoring the incidence and severity of adverse events using Common Terminology Criteria for Adverse Events v3.0.</measure>
    <time_frame>durante study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P53-SLP vaccine</intervention_name>
    <description>The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.</description>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent.

          -  Histological proven epithelial ovarian carcinoma.

          -  At least 4 weeks after termination of the last course of chemotherapy.

          -  Rising CA-125 serum levels after &quot;first line&quot; treatment and no measurable disease
             according to the RECIST (Response Evaluation Criteria in Solid Tumours) criteria, or
             Rising CA-125 serum levels after &quot;first line&quot; treatment with measurable disease
             according to the RECIST (Response Evaluation Criteria in Solid Tumours) criteria, but
             not willing or otherwise not fit to receive &quot;second line&quot; chemotherapy.

          -  Age 18 years or older, and an life expectancy of at least 3 months.

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial.

          -  Performance status 0 to 2 (WHO scale).

          -  Adequate hepatic, renal, and bone marrow function as defined:

        ASAT &lt; 100 U/l; ALAT &lt; 113 U/l; PT 9-12 seconds; APTT 23-33 seconds; creatinine &lt; 135
        μmol/l; WBC &gt; 3.0 x 109/L; platelets &gt; 100 x 109/L; hemoglobin &gt; 6.0 mmol/l.

        - Adequate venous access for blood collection and i.v. administration of cyclophosphamide.

        Exclusion Criteria:

          -  Pregnancy and / or breast feeding.

          -  (A)symptomatic cystitis.

          -  Other malignancies (previous or current), except basal or squamous cell carcinoma of
             the skin.

          -  Immunosuppressive agents, except for topical and inhalation corticosteroids.

          -  Prior therapy with a biological response modifier.

          -  Any other major disease that may interfere with the conduct of the study (e.g.
             uncontrolled hypertension, severe and/or unstable heart disease, neurological and
             psychiatric disorders).

          -  Signs or symptoms of CNS metastases.

          -  Known substance abuse (drug or alcohol).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. W. Nijman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, Melief CJ, van der Burg SH. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res. 2009 Feb 1;15(3):1086-95. doi: 10.1158/1078-0432.CCR-08-2227.</citation>
    <PMID>19188184</PMID>
  </reference>
  <reference>
    <citation>Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H. P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int J Cancer. 2007 Aug 1;121(3):606-14.</citation>
    <PMID>17415711</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. H.W. Nijman</name_title>
    <organization>University Medical Centre Groningen</organization>
  </responsible_party>
  <keyword>Ovarian cancer patients with recurrent disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

